
Razelle Kurzrock, MD, FACP
Center Associate Director, Professor
Locations
- Froedtert Hospital
- Cancer Center - Froedtert Hospital
Specialties
- Medical Oncology
Languages
- English
Cancer Center - Froedtert Hospital
Education
- MD - Doctor of Medicine
- FACP - Fellow of the American College of Physicians
Leadership Positions
- Associate Director of Clinical Research, Cancer Center
- Associate Director of Clinical Research, GSPMC
Publications
-
The best management for most patients with incurable cancer is on a clinical trial.
(Subbiah V, Kurzrock R.) Ann Oncol. 2025 Mar;36(3):240-243 PMID: 39550034 SCOPUS ID: 2-s2.0-85214022848 11/17/2024
-
(Liu J, Farrow M, Seymour L, Desai J, Loong HH, Ivy P, Koyoma T, Cook N, Blagden S, Garralda E, Massard C, Tolcher AW, Adashek JJ, Zhang L, Zhao S, Shen L, Kurzrock R, El-Deiry WS, Subbiah V, Joshua AM.) J Clin Oncol. 2025 Feb 20;43(6):735-747 PMID: 39808749 SCOPUS ID: 2-s2.0-85215858972 01/14/2025
-
Dual anti-CTLA-4 and anti-PD-1 blockade in metastatic basal cell carcinoma.
(Patel SP, Cano-Linson E, Chae YK, Schokrpur S, Lao CD, Powers BC, Victor AI, Onitilo AA, Shin S, Takebe N, Threlkel S, McLeod CM, Chen HX, Sharon E, Othus M, Ryan CW, Blanke CD, Kurzrock R.) NPJ Precis Oncol. 2025 Jan 24;9(1):24 PMID: 39856213 PMCID: PMC11759674 SCOPUS ID: 2-s2.0-85217839848 01/25/2025
-
(Chae YK, Corthell L, Patel SP, Edwards R, Scalici JM, Kim HS, Chung LI, Othus M, McLeod CM, Chen HX, Sharon E, Streicher H, Ryan CW, Blanke CD, Kurzrock R.) Clin Cancer Res. 2025 Jan 17;31(2):308-315 PMID: 39561273 PMCID: PMC11804806 SCOPUS ID: 2-s2.0-85215442127 11/19/2024
-
(Adashek JJ, Munoz JL, Kurzrock R.) Med. 2025 Jan 10;6(1):100550 PMID: 39689708 PMCID: PMC11725447 SCOPUS ID: 2-s2.0-85214329379 12/18/2024
-
Toll-like receptor 3: a double-edged sword
(Hsieh ML, Nishizaki D, Adashek JJ, Kato S, Kurzrock R.) Biomarker Research. December 2025;13(1) SCOPUS ID: 2-s2.0-85218427562 12/01/2025
-
Tumour-agnostic kinase inhibitors
(Adashek JJ, Nikanjam M, Kurzrock R.) Nature Reviews Drug Discovery. 2025 SCOPUS ID: 2-s2.0-86000326760 01/01/2025
-
SWOG/NCI Phase II Dual Anti-CTLA-4/PD-1 Blockade in Rare Tumors: Nonepithelial Ovarian Cancer.
(Chae YK, Othus M, Patel SP, Wilkinson KJ, Whitman-Purves EM, Lea J, Schallenkamp JM, Adra N, Appleman LJ, Alden M, Thomes Pepin J, Ellerton JA, Poklepovic A, Walter A, Rampurwala MM, Robinson WR, Kim HS, Chung LI, McLeod CM, Lopez G, Chen HX, Sharon E, Streicher H, Ryan CW, Blanke CD, Kurzrock R.) Clin Cancer Res. 2024 Dec 16;30(24):5593-5600 PMID: 39417692 PMCID: PMC11737520 SCOPUS ID: 2-s2.0-85212991277 10/17/2024
-
Measurable Residual Disease in Mantle Cell Lymphoma: The Unbearable Lightness of Being Undetectable.
(Cartagena J, Deshpande A, Rosenthal A, Tsang M, Hilal T, Rimsza L, Kurzrock R, Munoz J.) Curr Oncol Rep. 2024 Dec;26(12):1664-1674 PMID: 39641852 SCOPUS ID: 2-s2.0-85212713773 12/06/2024
-
Successful Targeting of Somatic VHL Alterations With Belzutifan in Two Cases.
(Thapa B, Shreenivas A, Bylow K, Chen HZ, George B, Kurzrock R.) J Immunother Precis Oncol. 2024 Nov;7(4):308-313 PMID: 39524464 PMCID: PMC11541926 SCOPUS ID: 2-s2.0-85208714820 11/14/2024
-
(Chae YK, Othus M, Patel S, Powers B, Hsueh CT, Govindarajan R, Bucur S, Kim HS, Chung LI, McLeod C, Chen HX, Sharon E, Streicher H, Ryan CW, Blanke C, Kurzrock R.) J Immunother Cancer. 2024 Sep 28;12(9) PMID: 39343510 PMCID: PMC11440191 SCOPUS ID: 2-s2.0-85205335139 09/30/2024
-
(Kurzrock R, Chaudhuri AA, Feller-Kopman D, Florez N, Gorden J, Wistuba II.) Cancer and Metastasis Reviews. December 2024;43(4):1217-1231 SCOPUS ID: 2-s2.0-85193072065 12/01/2024